Your browser doesn't support javascript.
loading
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload.
Mulvaney, Eamon P; Renzo, Fabiana; Adão, Rui; Dupre, Emilie; Bialesova, Lucia; Salvatore, Viviana; Reid, Helen M; Conceição, Glória; Grynblat, Julien; Llucià-Valldeperas, Aida; Michel, Jean-Baptiste; Brás-Silva, Carmen; Laurent, Charles E; Howard, Luke S; Montani, David; Humbert, Marc; Vonk Noordegraaf, Anton; Perros, Frédéric; Mendes-Ferreira, Pedro; Kinsella, B Therese.
Afiliação
  • Mulvaney EP; ATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Renzo F; ATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Adão R; Department of Surgery and Physiology, Cardiovascular R&D Centre-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Dupre E; IPS Therapeutique Inc., Sherbrooke, QC, Canada.
  • Bialesova L; ATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Salvatore V; ATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Reid HM; ATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Conceição G; Department of Surgery and Physiology, Cardiovascular R&D Centre-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Grynblat J; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Llucià-Valldeperas A; INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Michel JB; PHEniX Laboratory, Department of Pulmonary Medicine, Amsterdam UMC (Location VUMC), Amsterdam Cardiovascular Sciences, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Brás-Silva C; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, Netherlands.
  • Laurent CE; INSERM UMR_S 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France.
  • Howard LS; Department of Surgery and Physiology, Cardiovascular R&D Centre-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Montani D; IPS Therapeutique Inc., Sherbrooke, QC, Canada.
  • Humbert M; ToxiPharm Laboratories Inc., Ste-Catherine-de-Hatley, QC, Canada.
  • Vonk Noordegraaf A; Imperial College London, National Heart and Lung Institute, London, United Kingdom.
  • Perros F; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Mendes-Ferreira P; INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Kinsella BT; AP-HP, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Front Cardiovasc Med ; 9: 1063967, 2022.
Article em En | MEDLINE | ID: mdl-36588576
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irlanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irlanda